Definition and research guide
This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.
Content available: 4 complete abstracts (730 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.
Definition
The black substance in the ventral midbrain or the nucleus of cells containing the black substance. These cells produce dopamine, an important neurotransmitter in regulation of the sensorimotor system and mood. The dark colored melanin is a by-product of dopamine synthesis.
Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.
Also known as: Nigras, Substantia; Nigra, Substantia; Substantia Nigras.
Where it fits in the MeSH classification
- Broader topics
- Cerebral Peduncle
- Narrower topics
- Pars Compacta; Pars Reticulata
Related concepts
- Dopamine
- Melanin
Research landscape
PubMed indexes 17,299 records tagged with the MeSH heading “Substantia Nigra” (counts retrieved 2026-10-29). 2,004 of them (11.6%) were published from 2020 onward, and the busiest period so far is through 1999 with 7,780 records.
Reviews account for 1,341 records (7.8%) and meta-analyses for 35. Randomized controlled trials number 39 (0.2%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.
Show the data
| Period | Records |
|---|---|
| through 1999 | 7,780 |
| 2000-2009 | 3,765 |
| 2010-2019 | 3,750 |
| 2020 onward | 2,004 |
Publication-type chart data
| Type | Records | Share |
|---|---|---|
| Reviews | 1,341 | 7.8% |
| Meta-analyses | 35 | 0.2% |
| Randomized controlled trials | 39 | 0.2% |
Method: PubMed query "Substantia Nigra"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-29.
Reading the evidence in neuroscience
Neuroscience draws on tools with different strengths: cellular and animal work can manipulate circuits directly, while human imaging and electrophysiology observe the living brain at lower resolution. Small imaging studies are prone to false positives, and findings in animals do not always carry over to people. Clinical neurology and psychiatry rely on trials and cohort studies whose outcomes are often symptom scales. Check the species, the sample size, how the outcome was measured and whether results were replicated.
Evidence from open-access studies
These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.
| Study / authors | Year | Source label / design | Europe PMC citations | Licence / source |
|---|---|---|---|---|
| Oxidative stress in the aging substantia nigra and the etiology of Parkinson's disease | 2019 | Review article Design not recorded in structured metadata | 583 | cc by PMID 31432604 · DOI · PMC6826160 |
| A single-cell atlas of the human substantia nigra reveals cell-specific pathways associated with neurological disorders | 2020 | Research article Design not recorded in structured metadata | 283 | cc by PMID 32826893 · DOI · PMC7442652 |
| Unique functional responses differentially map onto genetic subtypes of dopamine neurons | 2023 | Research article Design not recorded in structured metadata | 167 | cc by PMID 37537242 · DOI · PMC10545540 |
| Integrated evaluation of Nigrosome 1 sign, neuromelanin-sensitive MR and iron deposition | 2026 | Research article Design not recorded in structured metadata | 1 | cc by PMID 40824349 · DOI · PMC12769993 |
Oxidative stress in the aging substantia nigra and the etiology of Parkinson's disease [1]
Abstract reading summary — source excerpts
- Opening excerpt
- Parkinson's disease prevalence is rapidly increasing in an aging global population.
- Closing excerpt
- We present a contemporary perspective on the central biochemical contribution of redox imbalance to Parkinson's disease etiology and argue that improving our ability to accurately measure oxidative stress, dopaminergic neurotransmission and cell death pathways in vivo is crucial for both the development of new therapies and the identification of novel disease biomarkers.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (202 words)
Parkinson's disease prevalence is rapidly increasing in an aging global population. With this increase comes exponentially rising social and economic costs, emphasizing the immediate need for effective disease-modifying treatments. Motor dysfunction results from the loss of dopaminergic neurons in the substantia nigra pars compacta and depletion of dopamine in the nigrostriatal pathway. While a specific biochemical mechanism remains elusive, oxidative stress plays an undeniable role in a complex and progressive neurodegenerative cascade. This review will explore the molecular factors that contribute to the high steady-state of oxidative stress in the healthy substantia nigra during aging, and how this chemical environment renders neurons susceptible to oxidative damage in Parkinson's disease. Contributing factors to oxidative stress during aging and as a pathogenic mechanism for Parkinson's disease will be discussed within the context of how and why therapeutic approaches targeting cellular redox activity in this disorder have, to date, yielded little therapeutic benefit. We present a contemporary perspective on the central biochemical contribution of redox imbalance to Parkinson's disease etiology and argue that improving our ability to accurately measure oxidative stress, dopaminergic neurotransmission and cell death pathways in vivo is crucial for both the development of new therapies and the identification of novel disease biomarkers.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 31432604 · DOI · PMC6826160
A single-cell atlas of the human substantia nigra reveals cell-specific pathways associated with neurological disorders [2]
Abstract reading summary — source excerpts
- Opening excerpt
- We describe a human single-nuclei transcriptomic atlas for the substantia nigra (SN), generated by sequencing approximately 17,000 nuclei from matched cortical and SN samples.
- Closing excerpt
- This atlas guides our aetiological understanding by associating SN cell type expression profiles with specific disease risk.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (150 words)
We describe a human single-nuclei transcriptomic atlas for the substantia nigra (SN), generated by sequencing approximately 17,000 nuclei from matched cortical and SN samples. We show that the common genetic risk for Parkinson's disease (PD) is associated with dopaminergic neuron (DaN)-specific gene expression, including mitochondrial functioning, protein folding and ubiquitination pathways. We identify a distinct cell type association between PD risk and oligodendrocyte-specific gene expression. Unlike Alzheimer's disease (AD), we find no association between PD risk and microglia or astrocytes, suggesting that neuroinflammation plays a less causal role in PD than AD. Beyond PD, we find associations between SN DaNs and GABAergic neuron gene expression and multiple neuropsychiatric disorders. Conditional analysis reveals that distinct neuropsychiatric disorders associate with distinct sets of neuron-specific genes but converge onto shared loci within oligodendrocytes and oligodendrocyte precursors. This atlas guides our aetiological understanding by associating SN cell type expression profiles with specific disease risk.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 32826893 · DOI · PMC7442652
Unique functional responses differentially map onto genetic subtypes of dopamine neurons [3]
Abstract reading summary — source excerpts
- Opening excerpt
- Dopamine neurons are characterized by their response to unexpected rewards, but they also fire during movement and aversive stimuli.
- Closing excerpt
- Our findings establish a connection between functional and genetic dopamine neuron subtypes and demonstrate that molecular expression patterns can serve as a common framework to dissect dopaminergic functions.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (140 words)
Dopamine neurons are characterized by their response to unexpected rewards, but they also fire during movement and aversive stimuli. Dopamine neuron diversity has been observed based on molecular expression profiles; however, whether different functions map onto such genetic subtypes remains unclear. In this study, we established that three genetic dopamine neuron subtypes within the substantia nigra pars compacta, characterized by the expression of Slc17a6 (Vglut2), Calb1 and Anxa1, each have a unique set of responses to rewards, aversive stimuli and accelerations and decelerations, and these signaling patterns are highly correlated between somas and axons within subtypes. Remarkably, reward responses were almost entirely absent in the Anxa1+ subtype, which instead displayed acceleration-correlated signaling. Our findings establish a connection between functional and genetic dopamine neuron subtypes and demonstrate that molecular expression patterns can serve as a common framework to dissect dopaminergic functions.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 37537242 · DOI · PMC10545540
Integrated evaluation of Nigrosome 1 sign, neuromelanin-sensitive MR and iron deposition [4]
Abstract reading summary — source excerpts
- Opening excerpt
- PurposeTo differentiate between Parkinson's Disease (PD) and healthy controls by using integrated analysis of PD-specific MR findings including deformation of the substantia nigra pars compacta (SNpc), signal loss in neuromelanin (NM) sensitive MRI, and iron deposition in the deep gray matter (DGM) structures.
- Closing excerpt
- Discriminating PD from controls was successful using each method: N1 sign (P ConclusionsIntegrated analysis of PD specific MR findings including N1 sign, NM volume, and iron content in the DGM structures robustly discriminates between PD and healthy controls.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (238 words)
PurposeTo differentiate between Parkinson's Disease (PD) and healthy controls by using integrated analysis of PD-specific MR findings including deformation of the substantia nigra pars compacta (SNpc), signal loss in neuromelanin (NM) sensitive MRI, and iron deposition in the deep gray matter (DGM) structures.Materials and methodsPatients with PD and healthy controls were recruited between August 2022 and December 2023. All subjects underwent 3 T MRI including a magnetization transfer contrast (MTC) and a double flip angle multi-echo protocol as part of Strategically Acquired Gradient Echo (STAGE). The data analysis included detecting the presence of Nigrosome-1 (N1) sign in the SNpc, signal intensity and volume of NM content and iron quantification through quantitative susceptibility mapping (QSM) in DGMs. The 3D regions of interest were manually demarcated on QSM maps. Mean susceptibility values from global analysis (whole structure) as well as regional high iron analysis (age-based threshold) were extracted for each individual structure. Univariate and multivariate analyses were performed using these parameters.ResultsNineteen patients with PD (68.0 ± 8.0 years, 10 males, Hoehn and Yahr scale 1 (n = 1), 2 (n = 13), 3 (n = 4), 4 (n = 1)) and 21 healthy controls (68.3 ± 8.6 years, 12 males) were enrolled. Discriminating PD from controls was successful using each method: N1 sign (P ConclusionsIntegrated analysis of PD specific MR findings including N1 sign, NM volume, and iron content in the DGM structures robustly discriminates between PD and healthy controls.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 40824349 · DOI · PMC12769993
Key reviews and meta-analyses
The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.
- Research article Parkinson disease [5]
- Research article Mesolimbocortical and nigrostriatal dopamine responses to salient non-reward events [6]
- Research article Glial reactions in Parkinson's disease [7]
- Research article Inflammation as a causative factor in the aetiology of Parkinson's disease [8]
- Research article Failure of the ubiquitin-proteasome system in Parkinson's disease [9]
- Research article Fetal nigral transplantation as a therapy for Parkinson's disease [10]
References
- Trist BG, Hare DJ, Double KL. Oxidative stress in the aging substantia nigra and the etiology of Parkinson's disease. . 2019. PMID 31432604 · DOI · PMC6826160
- Agarwal D, Sandor C, Volpato V, Caffrey TM, Monzón-Sandoval J, Bowden R, et al.. A single-cell atlas of the human substantia nigra reveals cell-specific pathways associated with neurological disorders. . 2020. PMID 32826893 · DOI · PMC7442652
- Azcorra M, Gaertner Z, Davidson C, He Q, Kim H, Nagappan S, et al.. Unique functional responses differentially map onto genetic subtypes of dopamine neurons. . 2023. PMID 37537242 · DOI · PMC10545540
- Fushimi Y, Ghassaban K, Sethi SK, Nakajima S, Okuchi S, Sakata A, et al.. Integrated evaluation of Nigrosome 1 sign, neuromelanin-sensitive MR and iron deposition. . 2026. PMID 40824349 · DOI · PMC12769993
- Balestrino R, Schapira AHV. Parkinson disease. Eur J Neurol. 2020. PMID 31631455 · DOI
- Horvitz JC. Mesolimbocortical and nigrostriatal dopamine responses to salient non-reward events. Neuroscience. 2000. PMID 10727783 · DOI
- McGeer PL, McGeer EG. Glial reactions in Parkinson's disease. Mov Disord. 2008. PMID 18044695 · DOI
- Whitton PS. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol. 2007. PMID 17339843 · DOI · PMC2013918
- McNaught KS, Olanow CW, Halliwell B, Isacson O, Jenner P. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci. 2001. PMID 11484002 · DOI
- Olanow CW, Kordower JH, Freeman TB. Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci. 1996. PMID 9054056 · DOI
About this article
- Sources
- NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
- Verification
- Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
- Review state
- automated source verified; no human expert review has been recorded yet.
- Version
- 1, last updated 2026-10-29.
See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.
Evidence strength
EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.